BR112016013946A2 - Quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos compostos e kit - Google Patents

Quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos compostos e kit

Info

Publication number
BR112016013946A2
BR112016013946A2 BR112016013946A BR112016013946A BR112016013946A2 BR 112016013946 A2 BR112016013946 A2 BR 112016013946A2 BR 112016013946 A BR112016013946 A BR 112016013946A BR 112016013946 A BR112016013946 A BR 112016013946A BR 112016013946 A2 BR112016013946 A2 BR 112016013946A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
quinazolin
thf
amines
kit
Prior art date
Application number
BR112016013946A
Other languages
English (en)
Other versions
BR112016013946A8 (pt
Inventor
Kehler Jan
Kyhn Rasmussen Lars
Langgård Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of BR112016013946A2 publication Critical patent/BR112016013946A2/pt
Publication of BR112016013946A8 publication Critical patent/BR112016013946A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

QUINAZOLIN-THF-AMINAS COMO INIBIDORES DE PDE1, COMPOSIÇÃO FARMACÊUTICA QUE OS COMPREENDE, PROCESSO PARA PREPARAÇÃO DA REFERIDA COMPOSIÇÃO FARMACÊUTICA, BEM COMO USO DOS COMPOSTOS E KIT. A presente invenção proporciona Quinazolin-THF-aminas como inibidores de PDE1 e seu uso como um medicamento, em particular para o tratamento de distúrbios neurodegenerativos e distúrbios psiquiátricos.
BR112016013946A 2013-12-19 2014-12-18 quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit BR112016013946A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300707 2013-12-19
DKPA201400249 2014-05-06
PCT/EP2014/078475 WO2015091805A1 (en) 2013-12-19 2014-12-18 Quinazolin-thf-amines as pde1 inhibitors

Publications (2)

Publication Number Publication Date
BR112016013946A2 true BR112016013946A2 (pt) 2017-08-08
BR112016013946A8 BR112016013946A8 (pt) 2018-01-30

Family

ID=52350066

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013946A BR112016013946A8 (pt) 2013-12-19 2014-12-18 quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit

Country Status (26)

Country Link
US (3) US20150175584A1 (pt)
EP (1) EP3083607B1 (pt)
JP (1) JP6419832B2 (pt)
KR (1) KR20160098269A (pt)
CN (1) CN105829300B (pt)
AP (1) AP2016009293A0 (pt)
AU (1) AU2014368601B2 (pt)
BR (1) BR112016013946A8 (pt)
CA (1) CA2933299A1 (pt)
CL (1) CL2016001488A1 (pt)
CR (1) CR20160282A (pt)
DO (1) DOP2016000152A (pt)
EA (1) EA201691108A1 (pt)
EC (1) ECSP16061208A (pt)
ES (1) ES2728079T3 (pt)
GE (1) GEP201706764B (pt)
IL (1) IL246230A0 (pt)
MX (1) MX2016007945A (pt)
PE (1) PE20160855A1 (pt)
PH (1) PH12016501173A1 (pt)
RU (1) RU2016125315A (pt)
SG (1) SG11201604936TA (pt)
SV (1) SV2016005220A (pt)
TN (1) TN2016000239A1 (pt)
TW (1) TW201609713A (pt)
WO (1) WO2015091805A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
DK3126354T3 (da) * 2014-04-04 2020-03-09 H Lundbeck As Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
TWI729109B (zh) * 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP7111720B2 (ja) 2016-12-28 2022-08-02 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ２阻害剤としての置換ピラゾロピリミジノン化合物
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002324846B2 (en) * 2001-08-31 2007-05-10 Childrens Hospital Medical Center Phosphodiesterase activity and regulation of phosphodiesterase 1-B-mediated signaling in brain
ZA200507228B (en) * 2003-04-01 2007-03-28 Applied Research Systems Inhibitors of phosphodiesterases in infertility
EP1751159A2 (en) * 2004-04-28 2007-02-14 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
EP1996587A1 (en) * 2006-02-23 2008-12-03 Pfizer Products Incorporated Substituted quinazolines as pde10 inhibitors
US20110190373A1 (en) * 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
WO2010132127A1 (en) * 2009-05-13 2010-11-18 Intra-Cellular Therapies, Inc. Organic compounds
EP2480537A1 (en) * 2009-09-24 2012-08-01 Basf Se Aminoquinazoline compounds for combating invertebrate pests
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺

Also Published As

Publication number Publication date
US20170267664A1 (en) 2017-09-21
AU2014368601B2 (en) 2018-07-05
AU2014368601A1 (en) 2016-06-30
CL2016001488A1 (es) 2016-12-09
WO2015091805A1 (en) 2015-06-25
PE20160855A1 (es) 2016-09-23
GEP201706764B (en) 2017-10-25
JP2017500339A (ja) 2017-01-05
EP3083607B1 (en) 2019-04-24
SG11201604936TA (en) 2016-07-28
TW201609713A (zh) 2016-03-16
CN105829300A (zh) 2016-08-03
RU2016125315A (ru) 2018-01-24
IL246230A0 (en) 2016-08-02
MX2016007945A (es) 2016-10-12
CN105829300B (zh) 2019-03-15
PH12016501173A1 (en) 2016-08-15
CA2933299A1 (en) 2015-06-25
US9701665B2 (en) 2017-07-11
US20150175584A1 (en) 2015-06-25
ECSP16061208A (es) 2017-08-31
JP6419832B2 (ja) 2018-11-07
KR20160098269A (ko) 2016-08-18
SV2016005220A (es) 2016-11-30
TN2016000239A1 (en) 2017-10-06
EP3083607A1 (en) 2016-10-26
EA201691108A1 (ru) 2016-09-30
AP2016009293A0 (en) 2016-06-30
ES2728079T3 (es) 2019-10-22
US20160318910A1 (en) 2016-11-03
BR112016013946A8 (pt) 2018-01-30
CR20160282A (es) 2016-09-06
DOP2016000152A (es) 2016-09-30
US10030007B2 (en) 2018-07-24

Similar Documents

Publication Publication Date Title
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
BR112017028318A2 (pt) compostos antibacterianos
CR20170478A (es) Compuestos novedosos
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
GT201600070A (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
UY35210A (es) Inhibidores de autotaxina
CL2017002719A1 (es) Imidazopirazinonas como inhibidores de pde1
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
BR112016013946A2 (pt) Quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos compostos e kit
BR112016025396A2 (pt) derivados de heterociclil-butanamida
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017008481A2 (pt) composto antimicótico
BR112015027399A2 (pt) ANTICORPOS ANTI-IGF-1R COM LIGAÇÃO DE FcRn ABOLIDA E SEU USO NO TRATAMENTO DE ENFERMIDADES VASCULARES OCULARES
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
BR112014018712A8 (pt) Derivados de morfolinila úteis como inibidores de mogat-2

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.